Increased myocardial vulnerability to ischemia-reperfusion injury in the presence of left ventricular hypertrophy

Journal of Hypertension

Volumn 34, Issue 3, 2016, Pages 513-523

  Mølgaard, Søren ^a   Faricelli, Barbara ^a   Salomonsson, Max ^a   Engstrøm, Thomas ^b   Treiman, Marek ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

exendin 4; left ventricular hypertrophy; mitochondria; myocardial infarction; postconditioning; reperfusion injury

Indexed keywords

CYTOCHROME A; CYTOCHROME B; CYTOCHROME C; CYTOCHROME C OXIDASE; CYTOCHROME C1; EXENDIN 4; UBIQUINOL CYTOCHROME C REDUCTASE; CYTOCHROME; INCRETIN; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OCCLUSION; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MITOCHONDRION; HEART RATE; HEART VENTRICLE WALL; HEART WEIGHT; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SPECTROPHOTOMETRY; ANIMAL; CARDIAC MUSCLE; COMPLICATION; DRUG EFFECTS; HEART; HEART INFARCTION; HYPERTENSION; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; CYTOCHROMES; ELECTRON TRANSPORT COMPLEX III; ELECTRON TRANSPORT COMPLEX IV; HEART; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCRETINS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SEVERITY OF ILLNESS INDEX; VENOMS;

EID: 84957570903     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000826     Document Type: Article

References (57)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357:1121-1135.
2. Hausenloy DJ, Bøtker HE, Condorelli G, Ferdinandy. Garcia-Dorado D, Heusch G, et al. Translating cardioprotection for patient benefit: position paper from the working group of cellular biology of the heart of the European Society of Cardiology. Cardiovasc Res 2013; 98:7-27.
3. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/ reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014; 66:1142-1174.
4. Hausenloy DJ, Baxter G, Bell R, Bøtker HE, Davidson SM, Downey J, et al. Translating novel strategies for cardioprotection: The Hatter Workshop recommendations. Basic Res Cardiol 2010; 105:677-686.
5. Levy D, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108:7-13.
6. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334-341.
7. Ma LL, Zhang FJ, Kong FJ, Qian LB, Ma H, Wang JA, Yan M. Hypertrophied myocardium is refractory to sevoflurane-induced protection with alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3" signals. Shock 2013; 40:217-221.
8. Penna C, Tullio F, Perrelli M-G, Moro F, Abbadessa G, Piccione F, et al. Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is lost as cardiac hypertrophy develops in nandrolone treated rats. Basic Res Cardiol 2011; 106:409-420.
9. Yano T, Miki T, Tanno M, Kuno A, Itoh T, Takada A, et al. Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection. Hypertension 2011; 57:110-115.
10. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87:1409-1439.
11. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014; 114:1788-1803.
12. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54:146-151.
13. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon-like peptide 1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005; 19:9-11.
14. Ban K, Noyan-Ashraf H, Hoefer J, Bolz S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation 2008; 117:2348-2358.
15. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317:1106-1113.
16. Timmers L, Henriques JPS, De Kleijn DPV, DeVries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Amer Coll Cardiol 2009; 53:501-510.
17. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Peptides 2008; 146:243-249.
18. Ossum A, Van Deurs U, Engstrøm T, Jensen JS, Treiman M. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 2009; 60:411-417.
19. Salling HK, Döhler KD, Engstrøm T, Treiman M. Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemiareperfusion injury in an isolated rat heart. Regul Peptides 2012; 178:51-55.
20. Treiman M, Elvekjær M, Engstrøm T, Jensen JS. Glucagon-like peptide 1: A cardiologic dimension. Trends Cardiovasc Med 2010; 20:8-12.
21. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33:1491-1499.
22. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, et al. Exenatide reduces final infarct size in patients with ST-segmentelevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012; 5:288-295.
23. Rustin P, Chretien D, Bourgeron T, Grard B, Riitig A, Saudubray JM, Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228:35-51.
24. Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 2011; 50:940-950.
25. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981; 101:593-600.
26. Rieske JS. Preparation and properties of reduced coenzyme Q-cytochrome c reductase (Compex III of the respiratory chain). Methods Enzymol 1967; 10:239-245.
27. Birch-Machin MA, Turnbull DM. Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol 2001; 65:97-117.
28. Williams JN. A method for the simultaneous quantitative estimation of cytochromes a, b, c1 and c in mitochondria. Arch Bioch Bioph 1964; 107:537-543.
29. Schneider H, Lemasters JJ, Höchli M, Hackenbrock C. Liposomemitochondrial inner membrane fusion. Lateral diffusion of integral electron transfer components. J Biol Chem 1980; 255:3748-3756.
30. Inserte J, Barrabes JA, Hernando V, Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res 2009; 83:169-178.
31. Ladilov Y, Efe O, Schafer C, Rother B, Kasseckert S, Abdallah Y, et al. Reoxygenation-induced rigor-type contracture. J Mol Cell Cardiol 2003; 35:1481-1490.
32. Di Lisa F, Canton M, Menabo R, Kaludercic N, Bernardi P. Mitochondria and cardioprotection. Heart Fail Rev 2007; 12:249-260.
33. Chen Q, Camara AKS, Stowe DF, Hoppel CL, Lesnefsky EJ. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion. Am J Physiol Cell Physiol 2007; 292:C137-C147.
34. Rouslin W. Mitochondrial complexes I, II, III, IV, and V in myocardial ischemia and autolysis. Am J Physiol Heart Circ Physiol 1983; 244:H743-H748.
35. Piper HM, Sezer O, Schleyer M, Schwartz P, Hutter JF, Spieckermann PG. Development of ischemia-induced damage in defined mitochondrial subpopulations. J Mol Cell Cardiol 1985; 17:885-896.
36. Lesnefsky EJ, Tandler B, Ye J, Slabe TJ, Turkaly J, Hoppel CL. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria. Am J Physiol HeartCirc Physiol 1997; 273:H1544-H1554.
37. Halestrap AP. A pore way to die: The role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010; 38:841-860.
38. Vanden Hoek TL, Li C, Shao Z, Schumacker PT, Becker LB. Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion. J Mol Cell Cardiol 1997; 29:2571-2583.
39. Ebrahim Z, Yellon DM, Baxter GF. Attenuated cardioprotective response to bradykinin, but not classical preconditioning, in DOCAsalt hypertensive left ventricular hypertrophy. Pharmacol Res 2007; 55:42-48.
40. Speechly-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning protects hypertrophied myocardium. Cardiovasc Res 1994; 28:1025-1029.
41. Wagner C, Ebner B, Tillack D, Strasser RH, Weinbrenner C. Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats. J Cardiovasc Pharmacol 2013; 61:35-41.
42. Dai W, Simkhovich B, Kloner RA. Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. Exp Gerontol 2009; 44:344-349.
43. Lucchinetti E, Jamnicki M, Fischer G, Zaugg M. Preconditioning by isoflurane retains its protection against ischemia-reperfusion injury in postinfarct remodeled rat hearts. Anesth Analg 2008; 106:17-23.
44. Lesnefsky EJ, Gudz TI, Migita CT, Ikeda-Saito M, Hassan MO, Turkaly PJ, et al. Ischemic injury to mitochondrial electron transport in the aging heart: damage to the iron-sulfur protein subunit of electron transport complex III. Arch Biochem Biophys 2001; 385:117-128.
45. Petrosillo G, Ruggiero FM, Di Venosa N, Paradies G. Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin. FASEB J 2003; 17:714-716.
46. Lesnefsky EJ, Chen Q, Slabe TJ, Stoll MSK, Minkler PE, Hassan MO, et al. Ischemia, rather than reperfusion, inhibits respiration through cytochrome oxidase in the isolated, perfused rabbit heart: role of cardiolipin. Am J Physiol Heart Circ Physiol 2004; 287:H258-H267.
47. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria. Central role of complex III. J Biol Chem 2003; 278:36027-36031.
48. Sluijter JPG, Condorelli G, Davidson SM, Engel FB, Ferdinandy P, Hausenloy DJ, et al. Novel therapeutic strategies for cardioprotection. Pharmacol Therap 2014; 144:60-70.
49. Nicholls DG, Ferguson SJ. Bioenergetics, vol. 4. Amsterdam: Elsevier; 2013.
50. Ong SB, Hall AR, Hausenloy DJ. Mitochondrial dynamics in cardiovascular health and disease. Antioxid Redox Signal 2013; 19:400-414.
51. Brazhe NA, Treiman M, Brazhe AR, Find NL, Maksimov GV, Sosnovtseva OV. Mapping of redox state of mitochondrial cytochromes in live cardiomyocytes using Raman microspectroscopy. PLoS One 2012; 7:e41990.
52. Pasdois P, Parker JE, Griffiths EJ, Halestrap AP. The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia. Biochem J 2011; 436:493-505.
53. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113:1535-1549.
54. Ussher JR. Deciphering ventricular GLP-1 action: time for a change of heart. Am J Physiol Heart Circ Physiol 2014; 307:H1390-H1392.
55. Lauerma K, Saeed M, Wendland MF, Derugin N, Yu KK, Higgins CB. The use of contrast-enhanced magnetic resonance imaging to define ischemic injury after reperfusion. Comparison in normal hypertrophied hearts. Invest Radiol 1994; 29:527-535.
56. Malek LA, Spiewak M, Klopotowski M, Petryka J, Mazurkiewicz L, Kruk M, et al. Influence of left ventricular hypertrophy on infarct size and left ventricular ejection fraction in ST-elevation myocardial infarction. Eur J Radiol 2012; 81:e177-e181.
57. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013; 381:166-175.